Description
Alfa D3-TEVA (alfacalcidol) Capsules 1 mcg. №30
Composition:
Alfacalcidol is the active ingredient in Alfa D3-TEVA capsules 1 mcg. Other ingredients may include gelatin, glycerol, and purified water.
Mechanism of Action:
Alfacalcidol, a synthetic form of vitamin D, works by increasing the intestinal absorption of calcium and promoting bone mineralization.
Pharmacological Properties:
Alfacalcidol is rapidly converted in the liver to calcitriol, the active form of vitamin D. It regulates calcium and phosphate metabolism, essential for bone health and neuromuscular function.
Indications for Use:
Alfa D3-TEVA is indicated for the management of hypocalcemia in patients with chronic renal failure and for the treatment of hypoparathyroidism to maintain calcium levels.
Contraindications:
Avoid Alfa D3-TEVA if you have hypersensitivity to alfacalcidol or any capsule ingredient. Consult your healthcare provider before initiating treatment.
Side Effects:
Common side effects may include hypercalcemia, hypercalciuria, and gastrointestinal disturbances. Monitor for signs of toxicity and adjust dosage accordingly.
Usage Instructions:
Take 1 capsule orally daily with water. It can be administered with or without food. Do not alter the dosage unless instructed by a healthcare professional.
Benefits Over Analogues:
Alfa D3-TEVA offers a precise dosage of alfacalcidol, ensuring consistent therapeutic efficacy in managing calcium disorders compared to traditional vitamin D supplements.
Suitable Patient Groups:
Alfa D3-TEVA is suitable for adults, including the elderly, and pediatric patients under medical supervision for calcium regulation in renal failure and hypoparathyroidism.
Storage and Shelf Life:
Store Alfa D3-TEVA in a cool, dry place below 25°C. Protect from light and moisture. Check the expiry date on the packaging and do not use after the stated period.
Packaging Description:
Alfa D3-TEVA is available in blister packs containing 30 capsules. Each capsule is imprinted with the product name and strength for easy identification.
Clinical Evidence and Effectiveness:
Clinical studies have demonstrated the efficacy of alfacalcidol in managing hypocalcemia and hypoparathyroidism. Notably, research in the Journal of Clinical Endocrinology and Metabolism highlighted alfacalcidol’s role in improving calcium levels in renal failure patients.
Additional Information:
Regular monitoring by healthcare providers is essential during Alfa D3-TEVA therapy to assess calcium levels and treatment response. Promptly report any adverse reactions or concerns to your physician.
